

AVIS DE SOUTENANCE DE THÈSE

DOCTORAT (Arrêté du 26 août 2022 modifiant l'arrêté du 25 mai 2016)

Madame Manon DE VRIES-BRILLAND

candidate au diplôme de Doctorat de l'Université d'Angers, est autorisée à soutenir publiquement sa thèse

le 27/09/2023 à 14h00

Institut de Cancérologie de l'Ouest

Amphithéâtre

15, rue André Boquel

49055 ANGERS

sur le sujet suivant :

Caractérisation du microenvironnement immunitaire des carcinomes papillaires du rein

Directeur de thèse : **Monsieur Mario CAMPONE**

Composition du jury :

Madame Laurence ALBIGES, PU-PH Institut Gustave Roussy, Villejuif, Co-directrice de thèse

Monsieur Yves ALLORY, PU-PH Institut Curie, Paris, Rapporteur

Monsieur Mario CAMPONE, Professeur des Universités Institut de Cancérologie de l'Ouest, Directeur de thèse

Madame Marine GROSS-GOUPIL, MD, PhD, Praticien hospitalier CHU de Bordeaux, Examineur

Monsieur Claude LINASSIER, PU-PH CHU de Tours, Rapporteur

Monsieur Bertrand MICHEL, Professeur Ecole Centrale de Nantes, Examineur

Monsieur Alain RAVAUD, PU-PH CHU de Bordeaux, Examineur

Résumé de la thèse

Papillary Renal Cell Carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC) and a distinct entity, although heterogenous, associated with poor outcomes. The treatment landscape of metastatic pRCC (mpRCC) relied so far on targeted therapies, mimicking previous developments in metastatic clear-cell renal cell carcinoma. However, antiangiogenics as well as mTOR inhibitors retain only limited activity in mpRCC. As development of immune checkpoint inhibitors (ICI) is now underway in patients with mpRCC, we aimed at discussing early activity data and potential for future therapeutic strategies in monotherapy or combination. Expression of immune checkpoints such as PD-L1 and infiltrative immune cells in pRCC could provide insights into their potential immunogenicity, although this is currently poorly described. Based on retrospective and prospective data, efficacy of ICI as single agent remains limited. Combinations with tyrosine-kinase inhibitors, notably with anti-MET inhibitors, harbor promising response rates and may enter the standard of care in untreated patients. Collaborative work is needed to refine the molecular and immune landscape of pRCC, and pursue efforts to set up.